Education ▼

SPECIALTY TOPICS

CURRENTLY VIEWING
Chronic Lymphocytic Leukemia

Breast Cancer

Gastrointestinal Cancer

Chronic Lymphocytic Leukemia

Acalabrutinib Achieves High Response Rates in CLL

Patients with newly diagnosed or relapsed/refractory chronic lymphocytic leukemia achieved objective response rates as high as 100% with either of 2 doses of the BTK inhibitor acalabrutinib, results of an open-label phase II trial showed.
Read More >>

ASH 2018: Venetoclax/Rituximab Combo Achieves Durable, High MRD-Negative Status in CLL

ASH 2018: Mutation in BCL2 Protein Confers Resistance to Venetoclax

ASH 2018: High MRD-Negative Rates Seen with Venetoclax in Patients With Relapsed/Refractory CLL

ASH 2018: Ibrutinib/Rituximab Improves OS, PFS Versus FCR for Untreated CLL

ASH 2018: Phase III Data Showcase PFS Benefit With Frontline Ibrutinib/Obinutuzumab Combo in High-Risk CLL

View More Stories >>

View Conference Coverage

2018 San Antonio Breast Cancer Symposium

2018 ASH Annual Meeting

2018 Ruesch Center Symposium

2018 Chemotherapy Foundation Symposium

2018 New York Lung Cancers Symposium

Dr. Shah Discusses the Criteria for Treatment Discontinuation in CLL

Dr. Seymour on Updated Findings From the MURANO Trial in CLL

Dr. Seymour on Role of Ibrutinib in CLL

Dr. Kahl on Promising Research in Chronic Lymphocytic Leukemia

Dr. Hill Discusses the Progression of CLL Treatment

OncLive houses thousands of videos that provide updates and information.
See more Videos

Evaluating CAR T-Cell Therapy Use

The Role of Transplant and Future of CLL

Other Promising Strategies in CLL

Maintenance and Frontline Therapy in CLL

OncLive houses thousands of videos that provide updates and information.
See more Videos

The Evolving Treatment Landscape of CLL

$Relapsed/Refractory CLL: Evaluating Other Novel Agents$

Relapsed/Refractory CLL: Evaluating Other Novel Agents

$Novel Approaches to Treating Relapsed/Refractory CLL$

Novel Approaches to Treating Relapsed/Refractory CLL

$Continuing Therapy in Relapsed/Refractory CLL$

$Evaluating Pharmacologic Agents in Relapsed/Refractory CLL$

CLL: Post-Ibrutinib or Chemoimmunotherapy Approaches

$Approaching Therapy for Relapsed/Refractory CLL$

OncLive houses thousands of videos that provide updates and information.
See more Videos

Featured Programs

Other Promising Strategies in CLL

This expert panel discussion led by William Wierda, MD, focuses on promising strategies available for the treatment of chronic lymphocytic leukemia. Dr. Wierda is joined in this discussion by Steven Coutre, MD; Matthew S. Davids, MD, MMSc; Nicole Lamanna, MD; and Shuo Ma, MD, PhD.